Diplomat Pharmacy Inc (NYSE:DPLO) fell 9.1% during trading on Wednesday . The stock traded as low as $5.31 and last traded at $5.37, 677,620 shares traded hands during trading. A decline of 37% from the average session volume of 1,083,013 shares. The stock had previously closed at $5.91.

Several brokerages recently commented on DPLO. Credit Suisse Group reissued a “sell” rating and set a $6.50 price target on shares of Deutsche Bank in a research report on Monday, April 29th. ValuEngine cut Zymeworks from a “buy” rating to a “hold” rating in a research report on Saturday, May 18th. Wells Fargo & Co set a $162.00 price target on Jazz Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, March 19th. Zacks Investment Research raised Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a research report on Tuesday. Finally, Raymond James set a $28.00 price target on Wheaton Precious Metals and gave the company a “buy” rating in a research report on Thursday, March 21st. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $9.96.

The firm has a market capitalization of $440.06 million, a P/E ratio of 26.85 and a beta of 1.07. The company’s 50-day moving average is $5.26. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.00 and a quick ratio of 0.66.

Diplomat Pharmacy (NYSE:DPLO) last released its quarterly earnings data on Tuesday, May 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.07 by ($0.26). Diplomat Pharmacy had a negative net margin of 5.85% and a positive return on equity of 1.38%. The business had revenue of $1.26 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same period in the previous year, the business earned ($0.01) earnings per share. The business’s quarterly revenue was down 6.4% on a year-over-year basis. As a group, research analysts predict that Diplomat Pharmacy Inc will post -0.53 earnings per share for the current year.

A number of large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its holdings in Diplomat Pharmacy by 2.2% during the 4th quarter. BlackRock Inc. now owns 8,650,451 shares of the company’s stock worth $116,435,000 after purchasing an additional 186,200 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Diplomat Pharmacy by 22.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,128,358 shares of the company’s stock worth $28,650,000 after purchasing an additional 395,246 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Diplomat Pharmacy by 97.5% during the 4th quarter. Bank of New York Mellon Corp now owns 1,682,590 shares of the company’s stock worth $22,648,000 after purchasing an additional 830,436 shares during the last quarter. FMR LLC lifted its holdings in Diplomat Pharmacy by 61.8% during the 4th quarter. FMR LLC now owns 1,189,312 shares of the company’s stock worth $16,008,000 after purchasing an additional 454,112 shares during the last quarter. Finally, Millennium Management LLC lifted its holdings in Diplomat Pharmacy by 7.1% during the 4th quarter. Millennium Management LLC now owns 673,940 shares of the company’s stock worth $9,071,000 after purchasing an additional 44,896 shares during the last quarter. 79.44% of the stock is owned by institutional investors and hedge funds.

About Diplomat Pharmacy (NYSE:DPLO)

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Recommended Story: How to Invest in Growth Stocks

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.